HIGHLIGHTS
- who: Elodie Bu00f4le-Richard and colleagues from the INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comtu00e9, Interactions Service Hu00e9matologie, CHU Besanu00e7on, Besancon, France have published the Article: CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm, in the Journal: Cancers 2022, 14, 2287. of 28/04/2022
- what: The authors report on novel and innovative therapies in development to target surface molecules in BPDCN currently in clinical trials or in preclinical stages. Flotetuzumab is currently being tested in a basket trial for relapsed/refractory CD123-positive malignancies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.